The AI-powered firm is unlocking the hidden therapeutic potential of crops by discovering energetic compounds that might goal particular situations. Subsequent up: diabetes and sleep issues.
For six weeks in July 2017, Lee Chae, a Stanford-educated plant biologist, sat at his kitchen desk in San Francisco—the place he can scent and listen to the Pacific Ocean—and opened up his laptop computer. It feels like a typical workday morning for a lot of, however Chae did one thing extra than simply fill out just a few spreadsheets. He started constructing a man-made intelligence platform that may determine bioactive compounds in crops and determine potential cures for particular human illnesses.
That very same yr, Chae, together with cofounders Jim Flatt and Sofia Elizondo, launched bioscience startup Brightseed to determine unknown compounds current in crops and develop them into numerous meals components, dietary supplements and medicines. For the final 5 years, the trio has been accumulating crops that people have been utilizing as meals and drugs for millennia, grinding them into powder, extracting the energetic chemical compounds and operating them by means of their AI platform—which they affectionately name “Forager”—to seek out the following blockbuster complement.
The corporate’s first discovery is a pair of compounds—N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)—present in hashish seed shells and black pepper which have proven promise in two preclinical research on mice to take away fats from the liver. The research, each of which had been printed in Cell Demise and Illness, a Nature peer-reviewed journal, counsel that these compounds might be used to handle non-alcoholic fatty liver illness, a persistent situation that afflicts a few quarter of the world’s inhabitants. Presently, there’s no FDA-approved treatment for NAFLD past encouraging sufferers to drop some weight and eat wholesome. Critical circumstances require weight-loss surgical procedure or perhaps a liver transplant.
“Hashish is understood for THC and CBD,” says Chae, naming the psychoactive part in pot that will get individuals excessive and the chemical compound related to anti-inflammation and different health-related advantages. “And but, there are these different two compounds which have been sitting in there in spite of everything this time and it’s a completely completely different chemical that helps us course of fats from the liver. It simply tells you ways little we all know, even of crops that we’ve got a really intimate data, that there’s nonetheless so much to find in how you need to use crops.”
“Take into consideration issues like aspirin, which got here from the bark of the willow tree, and metformin, which got here from the French lilac and is a first-line remedy for sort II diabetes—these all originated in crops.”
Headquartered in South San Francisco, Brightseed closed a $68 million Collection B spherical this month and the corporate has raised a complete of $120 million at what Forbes estimates to be a $300 million valuation. Brightseed is utilizing that capital to broaden its R&D and ramp up the commercialization of the 2 hemp seed compounds.
Hashish will not be the one plant the corporate is researching. Brightseed, which was named to the Forbes AI 50 record this yr, is on a mission to catalog the bioactive compounds within the approximate 60,000 edible plant species. To this point, it has a library of some 2 million compounds, and it has a objective of extracting 10 million by 2025. Elizondo, who used to work for Boston Consulting Group earlier than assembly Chae and Flatt, says Brightseed believes that people have solely scratched the floor in relation to figuring out and creating compounds present in crops that may profit individuals’s well being.
“The speculation is that nature is underexplored for its potential options for well being,” Elizondo says. “Vegetation are prolific producers of pure chemical compounds, a few of which we really feel, like caffeine, however there’s a bunch that we don’t really feel they usually’re answerable for sustaining our physique working at full capability. There are hundreds of thousands of bioactive compounds and pure chemical compounds on the market and we’ve solely actually tapped about 1%.”
Brightseed continues to be small—Forbes estimates its income is underneath $20 million—but it surely has some large companions. Danone, the milk and yogurt conglomerate, has tapped Brightseed to discover potential new plant-based components for its merchandise. And complement big Pharmavite, spice dealer OFI and Ocean Spray are additionally utilizing Brightseed in hopes to find new components related to wellness. Tobe Cohen, the chief progress officer of Pharmavite, says his firm struck a cope with Brightseed to make use of Forager to assist it create a brand new $100 million (annual gross sales) sleep complement model from a biocompound that Flatt says might assist extend individuals’s sleep with out them feeling groggy or “hungover.” “Compound discovery is out of attain until you’re within the pharmaceutical enviornment,” provides Cohen. “With the Forager database, it has opened up a technique to discover and uncover new biologically energetic plant compounds.”
Brightseed itself is launching a pipeline of chemical compounds centered on three areas: metabolic well being, cognitive operate and intestine well being. Subsequent up is a compound present in a plant—the founders gained’t say which plant—that might assist the physique handle blood glucose ranges, which is perhaps used together with diabetes treatment.
This isn’t Flatt’s first foray into well being dietary supplements. Along with serving because the chief of analysis and growth at meals startup Hampton Creek, he led R&D for Martek Biosciences, which commercialized DHA and omega-3—two lipids that promote mind and eye well being and are actually utilized in toddler formulation, milk and different merchandise. In 2011, Martek was acquired by DSM for $1.1 billion.
Chuck Templeton, the founding father of OpenTable and managing director at early Brightseed investor S2G Ventures, says Brightseed goes after big markets that lack options. The corporate’s first product targets non-alcoholic fatty liver illness, which at present has no pharmaceutical remedy and prices Individuals tens of billions of {dollars} a yr in healthcare. Templeton provides that Brightseed’s objective to create meals components and dietary supplements that assist handle large well being issues is a refreshing enterprise mannequin. “It’s a incredible staff hitting a incredible thought when all of the computational instruments are getting used to promote costly advertisements or to construct relationship websites—they’re utilizing it for phytonutrient discovery,” says Templeton.
Flatt has his personal spin on Brightseed’s mission, sounding like a cross between a biochemist and a shaman. “There’s a lot to be gained by conventional drugs,” he says. “Our ancestors understood that nature did, in truth, supply plenty of options to situations. Take into consideration issues like aspirin, which got here from the bark of the willow tree, and metformin, which got here from the French lilac and is a first-line remedy for sort II diabetes—these all originated in crops. This can be a well-proven strategy.”
MORE FROM AI 50 2022